Диссертация (1139554), страница 54
Текст из файла (страница 54)
Influence of interferon-alpha combined withchemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.// Int J Mol Sci 2014; 15: 4104-25.229. Khayat D., Weil M., Soubrane C., Jacquillat C. LAK cells and cancer immunotherapy. // Bulletin du Cancer. 1988; 75(1): 3-7.230. Kiessling R., Klein E., Wigzell H. "Natural" killer cells in the mouse. I.
Cytotoxiccells with specificity for mouse Moloney leukemia cells. Specificity and distributionaccording to genotype. // European Journal of Immunology. 1975; 5:112-117.231. Kim S., Poursine-Laurent J., Truscott S.M., et al. Licensing of NK cells by host majorhistocompatibility complex class I molecules // Nature. 2005; 436: 709-713.232. Kimura H., Iizasa T., Ishikawa A.
et al. Prospective Phase II Study of Post-surgicalAdjuvant Chemo-immunotherapy Using Autologous dendritic cells and activatedkiller cells from tissue culture of tumordraining lymph nodes in primary lung cancerpatients. // Anticancer Research. 2008; 28: 1229-1238.233. Kmiecik J., Zimmer J., Chekenya M. Natural killer cells in intracranial neoplasms:presence and therapeutic efficacy against brain tumours. // Neuro-Oncology. 2014;116(1): 1-9.234.
Knorr D., Bachanova V., Verneris M.R., Miller J.S. Clinical utility of natural killercells in cancer therapy and transplantation. // Sem in Imm. 2014; 26(2): 161-172.235. Kobayashi H., Shirakawa K., Kawamoto S. et al. Rapid accumulation and internalization of radiolabeled herceptinin anin ammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrastenhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). // Cancer Res.
2002; 62: 860-866.236. Koppe M.J., Bleichrodt R.P., Soede A.C. et al. Biodistribution and therapeutic ef cacyof 125/131I-, 186Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 tocarcinoembryonic antigen in mice with small peritoneal metastases of colorectalorigin. // J. Nucl. Med. 2004; 45: 1224-1232.237. Korbelik M., Krosl G., Krosl J., Dougherty G.J. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. // Cancer Research. 1996; 56: 5647-5652.280238.
Korbelik M., Sun J. Cancer treatment by photodynamic therapy combined with adoptive immunotherapy using genetically altered natural killer cell line. // Int. J. Cancer.2001; 93: 269-274.239. Kovalenko E.I., Abakushina E.V., Telford W. et al. Clustered carbohydrates as a target for natural killer cells: A model system // Histochem Cell Biol. 2007; 127(3): 313326.240. Kovalenko E.I., Khirova (Abakushina) E.V., Khaidukov S.V. et al.
CD15 and relatedoligosaccharides upregulate NK-cell-mediated cytotoxicity. Leucocyte typing VII(Ed. D. Mason et al.). Proceedings of VIIth International Workshop on Human Leucocyte Differentiation Antigenes, Oxford, Oxford University press. 2002. P. 183-185.241. Kovalenko E.I., Khirova (Abakushina) E.V., Molotkovskaya I.M. et al. The modification of cell surface with lipophilic glycoconjugates and the interaction of modifiedcells with natural killer cells. // Russ J Bioorganic Chem.
2004. 30, 250-60.242. Koyama S. Augmented human-tumorocytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12plus interleukin-2, and the phenotypic characterization of the cells in patients withadvanced carcinoma. // Cancer Res and Clin Oncol. 1997; 123(9): 478-484.243. Krause S.W., Gastpar R., Andreesen R. et al. Treatment of colon and lung cancerpatients with ex vivo heat shock protein 70-peptide-activated, autologous naturalkiller cells: a clinical phase I trial. // Clin Cancer Res. 2004; 10:3699-3707.244. Krieg S., Ullrich E.
Novel immune modulators used in hematology: impact on NKcells. // Front Immunol. 2013; 3: 388.245. Krmpotic A., Hasan M., Loewendorf A. et al. NK cell activation through the NKG2Dligand MULT-1 is selectively prevented by mouse cytomegalovirus gene m145. //Experimental Medicine. 2005; 201: 211-220.246. Lanier L.L.
NK cell recognition. // Ann Review of Immunology. 2005; 23: 225-274.247. Lee H.M., Kim K.S., Kim J. A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforminggrowth factor-beta. // Cellular Immunology. 2014; 290: 52-61.248. Levy S.M., Herberman R.B., Simons A., et al. Persistently low natural killer cell ac-281tivity in normal adults: immunological, hormonal and mood correlates.
// Natural immunity and cell growth regulation. 1989; 8: 173-186.249. Li K., Mandai M., Hamanishi J., et al. Clinical significance of the NKG2D ligands,MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator ofpoor prognosis. // Cancer Immunol. Immunother. 2009; 58: 641-652.250. Li P., Morris D.L., Willcox B.E., Steinle A., Spies T., Strong R.K. Complex structureof the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. //Nature Immunology. 2001; 2: 443-451.251. Li W., Xu L.P., Zhao L.D. et al. Cytokine-induced killer cell therapy for advancedpancreatic adenocarcinoma: a case report and review of the literature. // OncologyLetters. 2013; 5: 1427.252.
Li Y., Huang Q., Zhong Y., et al. Prospects in adoptive cell transfer therapy forсancer. // Journal of Cardiology and Clinical Research. 2013; 1: 1008.253. Lim O., Jung M.Y., Hwang Y.K., Shin E.C. Present and Future of Allogeneic NaturalKiller Cell Therapy. // Frontiers in Immunology. 2015; 6: 286.254.
Lin R.Y., Astiz M.E., Saxon J.C., Rackow E.C. Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. //Chest. 1993. P. 847-853.255. Lin S.J., Lee P.T., Kuo M.L. Cytokine activation of natural killer cells. // Methods inMolecular Biology. 2014; 1139: 223-229.256.
Litvinova L.S., Sokhonevich N.A., Gutsol A.A., Kofanova K.A. Influence of immunoregulatory cytokines (IL-2, IL-7 and IL-15) in vitro upon activation, proliferationand apoptosis of immune memory T-cells. // Tsitologia. 2013; 55(8): 566-71.257. Liu J., Sui J., Zhang Z. et al. Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokine-induced killer cells: a case report and review of the literature. // Oncology Letters. 2010; 1(6): 955-958.258. Ljunggren H.G., Karre K. In search of the 'missing self': MHC molecules and NKcell recognition. // Immunology Today. 1990; 11: 237-244.259.
Ljunggren H.G., Malmberg K.J. Prospects for the use of NK cells in immunotherapyof human cancer. // Nature Reviews Immunology. 2007; 7: 329-339.260. Lo P.H., Urabe Y., Kumar V. et al. Identification of a functional variant in the MICA282promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk. // PLoS One. 2013; 8(4): e61279.261. Lodolce J.P., Boone D.L., Chai S.
et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation // Immunity. 1998; 9: 669676.262. Logan N.F., Shannon W., Bryant J. et al. Preparation of viable tumour cell vaccinefrom human solid tumours: relationship between tumour mass and cell yield. // Melanoma Research.
1993; 3: 451-455.263. Long E.O. Negative signaling by inhibitory receptors: the NK cell paradigm. // Immunological Reviews. 2008; 224: 70-84.264. Lopez-Verges S., Milush J.M., Pandey S. et al. CD57 defines a functionally distinctpopulation of mature NK ceel in the human CD56dimCD16+ NK-cell subset. //Blood. 2010; 116(19): 3865-3874.265. Ma Y., Zhang Z., Tang L. et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. // Cytotherapy.2012; 14(4): 483-493.266. Mace E.M., Hsu A.P., Monaco-Shawver L. et al. Mutations in GATA2 cause humanNK cell deficiency with specific loss of the CD56bright subset.
// Blood. 2013; 121:2669-2677.267. Mamessier E., Sylvain A., Thibult M.L. et al. Human breast cancer cells enhanceself-tolerance by promoting evasion from NK cell antitumor immunity. The Journalof // Clinical Investigation. 2011; 121: 3609-3622.268. Mapara M.Y., Sykes M. Tolerance and Cancer: Mechanisms of Tumor Evasion andStrategies for Breaking Tolerance. // J of Clinical Oncology. 2004; 22: 1136-1151.269.
Marcenaro E., Della Chiesa M., Bellora F. et al. IL-12 or IL-4 prime human NK cellsto mediate functionally divergent interactions with dendritic cells or tumors. // Immunology. 2005; 17: 3992-3998.270. Marsh S.G., Parham P., Dupont B. et al. Killer-cell immunoglobulin-like receptor(KIR) nomenclature report, 2002. // Immunogenetics.
2003; 55(4): 220-226.271. Marten A., von Lilienfeld-Toal M., Buchler M.W., Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T283cell cytotoxicity. // Int J Cancer. 2006; 119: 2359-2365 [PubMed: 16929491]272. Martin G.S. Cell signaling and cancer. // Cancer Cell.
2003; 4: 167-174.273. Martin-Fontecha A., Thomsen L., Brett S. et al. Induced recruitment of NK cells tolymph nodes provides IFN-γ for TH1 priming. // Nature Imm. 2004. 5: 1260-1265.274. Matusali G., Tchidjou H.K., Pontrelli G. et al. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. // FASEB. 2013; 27(6): 2440-2450.275.
McGilvray R.W., Eagle R.A., Watson N.F. et al. NKG2D ligand expression in humancolorectal cancer reveals associations with prognosis and evidence for immunoediting. // Clinical Cancer Research. 2009. 15: 6993-7002.276. Mentlik James A., Cohen A.D., Campbell K.S. Combination immune therapies toenhance anti-tumor responses by NK cells. // Front Immunol. 2013; 4: 481.277. Milani V., Stangl S., Issels R. et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
